Maximizing the potential of cancer immunotherapy requires model systems that closely recapitulate human disease to study T-cell responses to tumor antigens and to test immunotherapeutic strategies. We have created a new system that is compatible with Cre-LoxP-regulatable mouse cancer models in which the SIY antigen is specifically overexpressed in tumors, mimicking clinically relevant TAAs. To show the utility of this system, we have characterized SIY-reactive T cells in the context of lung adenocarcinoma, revealing multiple levels of antigen-specific T-cell tolerance that serve to limit an effective antitumor response. Thymic deletion reduced the number of SIY-reactive T cells present in the animals. When potentially self-reactive T cells in the periphery were activated, they were efficiently eliminated. Inhibition of apoptosis resulted in more persistent self-reactive T cells, but these cells became anergic to antigen stimulation. Finally, in the presence of tumors overexpressing SIY, SIY-specific T cells required a higher level of costimulation to achieve functional activation. This system represents a valuable tool in which to explore sources contributing to T-cell tolerance of cancer and to test therapies aimed at overcoming this tolerance. [Cancer Res 2008;68(22):9459-68] 
Introduction
Mouse models have been a mainstay of cancer immunology research. The mouse has been used to probe the function of cells and molecules that influence the ability of tumor-reactive T cells to kill or to otherwise become functionally suppressed, or tolerized (1) (2) (3) . These studies have largely relied on chemically induced and spontaneous tumors in immunodeficient mice or on transplanted tumors. Such systems are limited because they fail to reproduce the complex interactions that exist among an emerging tumor, its microenvironment, and the multiple elements of an intact immune system. More recently, genetically engineered cancer models with tissue-specific expression of known antigens have been used to study T cells reactive to tumor antigens (4) (5) (6) (7) (8) (9) . Interestingly, these studies have led to divergent findings on T-cell reactivity and tolerance to tumors, leading to the question of whether to attribute these differences to the immunobiology of specific tissues, the type of cancer under study, and/or the pattern in which antigens are expressed.
Tumor antigens are characterized as either tumor-specific (TSA) or tumor-associated (TAA). TSAs are derived from proteins to which the host immune system is naïve, such as mutant, germ cellrestricted, or viral proteins. TAAs, on the other hand, are derived from wild-type somatic proteins overexpressed or inappropriately expressed in tumors (e.g., carcinoembryonic antigen, ERBB2, hTERT, MUC1, P53). Experimental immune therapies for both TSAs and TAAs are being pursued as neither is clearly a more effective anticancer target (10) (11) (12) . Targeting TSAs might seem preferable because this provides absolute selection for tumor cells; however, TSA expression is often limited to the individual tumors from which they were originally identified (13) . Conversely, TAAs are commonly shared among tumor types and represent the majority of known tumor antigens (14) . Thus, therapies developed to TAAs may be applicable to patients across cancer types.
Lung cancer is the leading cause of cancer death worldwide. This is due to its high incidence and the failure of existing therapies to effectively treat advanced disease. Thus, there is great need to develop effective novel therapeutic strategies for lung cancer. Relative to other tumor types (e.g., melanoma, ovarian, and prostate cancer), little is known about the immune response to lung cancer or the potential for immunotherapy for this cancer type (15) (16) (17) (18) (19) . To begin to explore the immune response to lung cancer antigens and to build systems for testing immunotherapeutic strategies to treat lung cancer in humans, we have created a mouse model in which the well-characterized T-cell antigen SIYRYYGL (20) is overexpressed in autochthonous lung cancer. Based on analysis of T cells reactive to SIYRYYGL in this context, we have uncovered multiple levels of immune tolerance that limits an effective T-cell response against a TAA ( Supplementary  Fig. S1 ).
Materials and Methods
Mice. 2C mice were provided by J. Chen (Massachusetts Institute of Technology, Cambridge, MA), Trp53 flox mice were provided by A. Berns (The Netherlands Cancer Institute, Amsterdam, the Netherlands), and Meox-Cre and Rag2 À mice were purchased from The Jackson Laboratory. K-ras LSL-G12D mice were generated in our laboratory (21, 22) . R26 LSL-LSIY mice and controls used were either pure 129S4/SvJae or enriched on C57BL/6 3-13 generations. Donor 2C cells for transfer experiments were from pure C57BL/ 6 2C;Rag2 À/À mice and recipients were always C57BL/6 enriched. To induce tumors, mice were infected with Adenovirus-Cre (Ad-Cre) intranasally as previously described (21) . WSN-SIY was provided by J. Chen and infections were done by intranasal instillation similar to Ad-Cre. For tumor studies, lung histology was prepared and analyzed by Bioquant Image Analysis software as previously described (21) . Animal studies were approved by Massachusetts Institute of Technology's (MIT) Committee for Animal Care and conducted in compliance with Animal Welfare Act Regulations and other federal statutes relating to animals and experiments involving animals, and adheres to the principles set forth in the 1996 National
Research Council Guide for Care and Use of Laboratory Animals (institutional animal welfare assurance number, A-3125-01). Cells. Mouse embryonic fibroblasts (MEF) were derived from e13.5 embryos and grown as previously described (22) . KP/KPLSIY cell lines were derived from K-ras LSL-G12D/+ ;p53 flox/flox mice (23) 16 wk post-Ad-Cre. Individual tumors were plucked from lungs, minced, trypsinized, and cultured in MEF growing medium until lines were established. DC2.4.LSIY cells were generated by infection of DC2.4 cells (24) with a lentivirus bearing Luciferase-SIY and selection of a single positive clone. In vitro activated 2C cells were made by stimulating 2C splenocytes/lymphocytes suspensions with 1 Ag/mL SIY in DMEM-10 full medium overnight, then culturing with 10ng/mL mIL-2 (R&D Systems) for 6 d. Bcl2 overexpression was achieved by spin-infecting in vitro activated 2C cells twice (at days 3 and 4 of activation) with a pMSCV-IRES-GFP retrovirus carrying Bcl2, prepared as described (25) .
Luciferase detection. Cells were lysed with Passive Lysis Buffer (Promega) and assayed with Luciferase Assay Reagent (Promega) according to manufacturer's instructions. Tissues and tumors were mechanically disrupted before lysis and tissue debris was pelleted before assay. In vivo bioluminescence imaging was performed on a NightOWLII LB983 (Berthold Technologies). Mice were shaved and i.p. injected with Beetle Luciferin (Promega) within 20 min before imaging.
Cell transfer and DC vaccination. Single-cell suspensions from lymph nodes and spleens of 2C;Rag2
1Lox-LSIY/+ , and R26 +/+ mice were used for 2C transfer, in vivo cytotoxicity assay's target, and control cells, respectively. Cells were counted by hemocytometer, resuspended in RPMI, and transferred into recipients via tail vein. For CFSE-labeling, cells were resuspended at 4 to 6 Â 10 6 cells/mL RPMI with 5% FCS containing 5 Amol/L (or 1 Amol/L for control cells in in vivo cytotoxicity assay) CFSE (Molecular Probes) for 10 min at 37jC. Cells were then washed twice in RPMI with 5% FCS, followed by washes in serum-free RPMI before i.v. transfer into recipients. Cells (3 Â 10 6 ) were injected for naïve 2C transfer, 12 Â 10 6 cells for in vitro activated 2C, and 6 Â 10 6 cells each of CFSE-labeled target and control in vivo cytotoxicity cells. DC2.4.LSIY cells were washed and resuspended in RPMI for i.p. vaccination with 5 Â 10 5 cells per mouse. Cell isolation. Single-cell suspensions from lymph nodes, spleen, and thymus were generated by mechanical disruption. For lung preparations, tissue samples were minced and digested at 37jC for 30 min in 125 U/mL of collagenase-typeI (Life Technologies) in PBS before mechanical disruption and passage through a 70 Am-pore filter (BD Falcon). Peripheral blood was collected by tail tip bleeds into 40 AL of 50 mmol/L EDTA to prevent coagulation. RBC were lysed with an aqueous solution containing 0.83% NH 4 Cl, 0.1% KHCO 3 , and 0.000037% Na 2 EDTA at pH 7.2 to 7.4. Single-cell suspensions were passed through a 35-Am-pore cell-strainer cap (BD Falcon) before culture, i.v. transfer, or staining for flow cytometry.
Reagents and flow cytometry. SIYRYYGL peptide was synthesized by MIT's Biopolymers Laboratory. Recombinant murine IFN-g was purchased from PeproTech, Inc. The following antibodies were purchased from BD Pharmingen: aCD4(H129.19), aCD8(53-6.7), aCD11b (M1/70), aCD16/ CD32(2.4G2), aCD25(7D4 and PC61), aCD44(IM7), aCD69(H1.2F3), aCD107a (1D4B), aGr-1(RB6-8C5), aH-2K b (AF6-88.5), and aIgG 1 (X56). Phycoerythrin-conjugated and unconjugated DimerX I reagents were purchased from BD Pharmingen and prepared according to manufacturer's instructions. Intracellular Foxp3 staining was performed with FITC-amouse/rat Foxp3 staining set from eBioscience and secreted IFN-g capture/ detection was performed with Mouse IFN-g Secretion Assay Detection kit from Miltenyi Biotec, according to manufacturers' instructions. Biotinylated 1B2 monoclonal antibody was provided by J. Chen. Streptavidin-allophycocyanin and streptavidin-phycoerythrin conjugates were purchased from BD Pharmingen. Cells were read on a FACSCalibur (BD Biosciences) and analyzed using Flowjo 8.1 software (Tree Star, Inc). Dead cells were excluded by 1 Ag/mL propidium iodide staining (Sigma). LSL-LSIY exhibits Cre-dependent overexpression. Central tolerance could occur due to thymus-restricted or ubiquitous, somatic antigen expression. Various tissues were surveyed to distinguish between these possibilities. Luciferase activity was 3-to 30-fold higher in both thymic and extrathymic tissues of R26 LSL-LSIY/+ mice relative to background levels in controls (Fig. 1C) . By contrast, in R26 1Lox-LSIY/+ mice, in which the STOP element had been deleted by the Meox2-Cre transgene (31), a 10 4 -to 10 5 -fold increase in reporter activity was detected in all tissues examined ( Fig. 1C; Supplementary Fig. S2A ). These results show that R26 LSL-LSIY exhibits low-level, ubiquitous expression of LSIY.
Results

Generation of
To further characterize the consequences of low-level expression from R26 LSL-LSIY , we assessed 2C cell reactivity to R26 LSL-LSIY/+ cells. Naïve 2C cells exhibited dose-dependent activation (measured by CD25 surface-expression) and proliferation upon coculture with R26 LSL-LSIY/+ , but not with R26 +/+ , splenocytes (Supplementary Fig. S3A and B). Additionally, transfer of CFSE-labeled 2C cells into R26
LSL-LSIY /+ mice led to progressive dilution of CFSE and up-regulation of CD44, a cell-adhesion molecule associated with T-cell activation ( Fig. 1D; Supplementary Fig. S3C ). These data establish that low-level LSIY expression from R26 LSL-LSIY is sufficient to stimulate 2C cells in vitro and in vivo.
Incomplete mice, albeit at significantly lower levels compared with controls (SIY-reactive T cells were not detectable in uninfected mice; data not shown; Fig. 2A ).
Because SIY-reactive T cells in R26 LSL-LSIY mice could be selfreactive, we probed the activity of these cells induced by WSN-SIY and found they were functional. When single-cell suspensions from lungs of WSN-SIY-infected mice were stimulated in vitro with SIY, a comparable fraction of cells secreted IFN-g in both R26
+/+ and R26 LSL-LSIY/+ cultures (Fig. 2B) . Furthermore, by assaying in vivo cytotoxicity ( Supplementary Fig. S4 ) in WSN-SIY-infected mice, we found SIY-specific cytolysis in proportion to SIY-reactive T cells induced in R26
LSL-LSIY/+ mice ( were evident in WSN-SIY-infected wild-type mice (Fig. 2D) . Together, these results show that central tolerance to SIY is incomplete in R26 LSL-LSIY mice and a transient, but functional, T-cell response to SIY can be initiated.
Antigen-overexpressing tumors progress normally. R26
LSL-LSIY is a novel system in which overexpression of a self-antigen is induced, representing clinically relevant TAAs in human cancer (13) . Given the importance of TAAs as targets for cancer immunotherapy, R26 LSL-LSIY in Cre-inducible cancer models provides a powerful tool to study T cell-tumor interactions. To explore the utility of this system, we used a model of human lung adenocarcinoma in which oncogenic K-ras is expressed from its endogenous locus after intranasal Ad-Cre administration (21, 22) . In this K-ras LSL-G12D model, focal activation of oncogenic K-ras leads to epithelial hyperplasia, which progresses to adenoma and adenocarcinoma over a defined time course resembling human non-small cell lung cancer (NSCLC).
We generated K-ras LSL-G12D/+ ;R26 LSL-LSIY/+ mice and induced lung cancer in these animals and controls using Ad-Cre. K-ras LSL-G12D/+ ; R26 LSL-LSIY/+ mice developed lung tumors histologically indistinguishable from their K-ras LSL-G12D/+ ;R26 +/+ littermates when examined at various times after Ad-Cre (data not shown; 3 -to 10 4 -fold higher luciferase activity than those from K-ras LSL-G12D/+ ;R26 +/+ mice, suggesting that LSIY expression was maintained in established tumors (Fig. 3B) . Luciferase activity was also detectable in large tumors several months after tumor initiation via in vivo bioluminescence imaging (Fig. 3C) .
Histologic examination of tumors from K-ras littermates, but no significant differences were observed (Fig. 3D) . These data suggest that although SIY-reactive T cells are elicited in WSN-SIY-infected R26 LSL-LSIY/+ mice (Fig. 2) , a response is not generated against SIY-overexpressing lung tumors. Tumors maintain antigen presentation. Tumor-specific down-regulation of antigen presentation has been proposed as a mechanism to evade recognition by T cells (34) (35) (36) . To measure MHC class I in tumors, lung tumor cell lines were derived from Ad-Cre-infected K-ras LSL-G12D/+ ;p53 fl/fl ;R26 LSL-LSIY/+ mice and R26
+/+ controls ( Supplementary Fig. S5A and B) . By flow cytometry, we detected comparably low levels of H-2K b , which was induced 40-fold by IFN-g treatment in all lines (Supplementary Fig. S5C ). This indicates that antigen presentation is functional in tumors. Furthermore, we induced and examined lung tumors in mice on a 2C transgenic background. Tumors in K-ras LSL-G12D/+ ;R26 LSL-LSIY/+ ;2C mice were highly infiltrated by lymphocytes in contrast to tumors induced in K-ras LSL-G12D/+ ;R26 +/+ ;2C controls, demonstrating that antigen presentation by SIY-overexpressing tumors is sufficient to recruit 2C cells in vivo (Supplementary Fig. S5D ). These observations imply that loss of SIY presentation is unlikely to account for the unproductive immune response to SIY-overexpressing tumors.
Naïve cells recognize but do not respond effectively to lung tumors. Our data indicate that SIY-reactive T cells are present in K-ras LSL-G12D/+ ; R26 LSL-LSIY/+ animals but fail to react to SIYoverexpressing lung tumors. There are several nonexclusive explanations for this observation. For example, neither tumor initiation nor progression may be a sufficient stimulus to induce T-cell responses to TAAs (36) . Alternatively, peripheral tolerance to self-antigen may inhibit responses to overexpressed antigens in tumors (37) . Finally, tumors overexpressing antigen could be actively suppressing reactive T cells (2, 38) . Because the low numbers of endogenous SIY-specific T cells in R26 LSL-LSIY mice impedes analyses, we investigated these possible mechanisms by transferring donor 2C cells into tumor-bearing and control animals.
Naïve 2C cells became activated and proliferated in tumorbearing K-ras LSL-G12D/+ ;R26 LSL-LSIY/+ animals, similar to our observation in tumor-free R26 LSL-LSIY/+ mice (Figs. 4A and B, and Supplementary Figs. S3C, and S1F). Only in tumor-bearing K-ras LSL-G12D/+ ;R26 LSL-LSIY/+ mice, however, were 2C cells enriched in lung-draining mediastinal lymph nodes relative to nondraining mesenteric lymph nodes (Fig. 4C ). 2C cells are likely retained in mediastinal lymph nodes where SIY antigen presentation is increased due to SIY-overexpressing lung tumors.
Despite accumulation in high SIY areas, 2C cells did not infiltrate tumors, although 2C cells were detectable in lungs by flow cytometry (data not shown; Fig. 4C ). Consistent with the absence of tumor-infiltrating lymphocytes, K-ras LSL-G12D/+ ;R26 LSL-LSIY/+ mice displayed no decrease in tumor burden, size, or number relative to K-ras LSL-G12D/+ ;R26 +/+ mice analyzed 4 weeks after 2C transfer (Fig. 4D) . These data show that 2C cells do not hinder tumor growth. Moreover, 2C cells were not detectable in any mice at this time point whether they bore tumors or not (data not shown). These data indicate that 2C cells activated in R26 LSL-LSIY mice do not form memory cells, as was observed in WSN-SIY-infected R26 LSL-LSIY mice, potentially due to peripheral tolerance where persistent weak TCR stimulation leads to apoptosis (37) . Therefore, in the presence of self-antigen, SIY-reactive T cells become activated and divide but do not significantly kill tumor cells or persist.
SIY-reactive T cells are not cytotoxic in R26 LSL-LSIY mice.
Failure of T cells to kill SIY-overexpressing tumors could be due to a general defect in SIY-specific cytotoxicity or to a direct inhibition of T cells by tumors. To assess 2C cell functionality, we assayed in vivo cytotoxicity examining the ability of 2C cells to kill nonmalignant target cells ( Fig. 5A; Supplementary Fig. S4 ). As shown in Fig. 5C , DC2.4.LSIY vaccination stimulated 2C cells to become highly cytotoxic in wild-type animals, a positive control for SIY-specific cytotoxicity. As a negative control, naïve 2C cells transferred into R26 +/+ without vaccination do not become activated and, thus, only displayed low SIY-specific cytolysis.
The assay was applied to tumor-free R26 LSL-LSIY/+ mice. Despite inducing activation markers and proliferating, 2C cells exhibited no more cytotoxicity in these animals than 2C cells in R26 +/+ mice, indicating that self-antigen-induced activation fails to yield full effector function (Figs. 4A and B, and 5B). In tumor-bearing K-ras LSL-G12D/+ ;R26 LSL-LSIY/+ animals, SIY-specific cytotoxicity was similarly defective (Fig. 5B) . These data show generalized impairment in T-cell cytotoxicity to antigenic targets, rather than specific inhibition of tumoricidal activity in R26 LSL-LSIY mice. TAA-overexpressing tumors suppress T-cell cytotoxicity. Peptide presentation without costimulation often yields unproductive activation and T-cell deletion analogous our observations (39) . To determine whether DC2.4.LSIY could provide the necessary costimulation to functionally activate 2C cells in animals in which SIY is a self-antigen, naïve 2C cells were transferred into R26 LSL-LSIY/+ animals concurrently with DC2.4.LSIY vaccination (Fig. 5A) . With this treatment, 2C cells exhibited high levels of SIY-specific cytotoxicity in tumor-free animals, despite low-level ubiquitous SIY (Fig. 5B and C) . This result shows that self-antigen presented with ample costimulation can yield functional activation of potentially self-reactive T cells.
When 2C cells were transferred into tumor-bearing K-ras LSL-G12D/+ ; R26 LSL-LSIY/+ mice with DC2.4.LSIY vaccination, however, only marginal induction of SIY-specific cytotoxicity was observed ( Fig. 5B and C) . Thus, although costimulation enabled 2C cells to become highly cytotoxic to self-antigen in tumor-free animals, it failed to similarly induce SIY-specific cytotoxicity in the presence of tumors overexpressing SIY. Importantly, 2C transfer and DC2.4.LSIY vaccination of tumor-bearing K-ras LSL-G12D/+ ;R26 +/+ mice resulted in robust SIY-specific cytotoxicity (Fig. 5B) . This result strongly supports a mechanism by which tumors induce suppression of immune responses toward antigens overexpressed in those tumors. Furthermore, we observed comparably low cytotoxicity in mediastinal lymph nodes draining tumor-bearing lungs and mesenteric lymph nodes not draining tumors, suggesting that tumor-induced inhibition of TAA-specific T cells occurs systemically ( Fig. 5C; data not shown) .
Functional activation of TAA-reactive T cells requires stronger costimulation. The balance of immune stimulatory and inhibitory factors determines whether immune reactivity or tolerance is generated. Therefore, we reasoned that stronger immunologic stimuli might induce SIY-specific cytotoxicity in tumor-bearing R26 LSL-LSIY/+ mice. DC2.4.LSIY vaccination failed to expand endogenous SIY-reactive T cells to detectable levels in R26 LSL-LSIY/+ mice (data not shown), whereas WSN-SIY was more potent (Fig. 2) . Thus, we used WSN-SIY instead of DC2.4.LSIY to vaccinate naïve 2C cell recipients (Fig. 5A) . In contrast to the case with DC2.4.LSIY vaccination, WSN-SIY vaccination caused 2C cells to exhibit high SIY-specific cytotoxicity in both tumor-free and tumor-bearing R26 LSL-LSIY/+ mice (Fig. 5D ). This result indicates that the threshold costimulation required to induce SIY-specific cytotoxicity is increased in the presence of SIY-overexpressing tumors. Despite being highly cytotoxic, however, 2C cells did not seen to exert a significant antitumor effect in WSN-SIY-infected K-ras LSL-G12D/+ ;R26 LSL-LSIY/+ mice, although the number of animals tested was small (data not shown). This phenomenon is likely a result of the relatively brief life span of 2C cells in R26 LSL-LSIY mice. SIY-reactive T cells blocked from death succumb to anergy. We have shown that SIY-reactive T cells can be functionally activated in tumor-bearing R26 LSL-LSIY/+ mice, but as these cells are short-lived, T-cell death remains an obstacle to effective antitumor immunity. To overcome this barrier, we overexpressed anti-apoptotic Bcl2 by infecting SIY-stimulated 2C cells with a retrovirus carrying Bcl2 and enhanced green fluorescent protein EGFP (MIG-Bcl2). By observing enrichment of EGFP + cells in culture, we confirmed that Bcl2-overexpressing 2C cells had enhanced survival over uninfected cells when deprived of IL-2 ( Fig. 6A; ref. 40) . When MIG-Bcl2-infected 2C cells were transferred into R26
LSL-LSIY/+ and R26 +/+ mice, Bcl2-overexpressing cells again became enriched over uninfected cells in both genotypes (Fig. 6B) . Despite this enrichment, 2C cells in R26 LSL-LSIY/+ mice was still significantly reduced and decreased over time compared with 2C cells in R26 +/+ recipients, suggesting that induction of both intrinsic and extrinsic apoptotic pathways account for loss of 2C cells.
Next, we examined the function of persisting Bcl2-overexpressing 2C cells. Upon in vitro SIY stimulation of splenocytes recovered from 2C recipients, we observed that 2C cells from R26 LSL-LSIY/+ mice had impaired IFN-g secretion compared with controls (Fig. 6C) . Therefore, although Bcl2 overexpression can partially protect 2C cells from apoptosis in the presence of self-antigen, additional mechanisms act to induce anergy in these cells.
Discussion
We have described a novel system that allows inducible expression of a defined antigen in mice to mimic TAAs in human cancer. We have characterized T cells reactive to the SIY TAA in lung adenocarcinoma and uncovered multiple levels of immune tolerance that limit an effective response against TAAs (model depicted in Supplementary Fig. S1 ). Due to low-level antigen expression, SIY-reactive T cells were subjected to central tolerance, eliminating the majority of potentially tumor-and selfreactive T cells during development. In the periphery, SIY-reactive cells that escaped thymic selection died soon after activation, likely a mechanism to limit autoreactivity. Self-reactive T cells that were transiently blocked from apoptosis became anergic. Finally, in mice bearing autochthonous SIY-overexpressing lung tumors, strong immunologic stimuli were required to activate transferred 2C cells to become highly cytotoxic toward targets. This is noteworthy because a weaker vaccine was able to impart cytotoxic activity on self-reactive T cells only in the absence of SIY-overexpressing tumors. Thus, in the context of a TAA, reactive T cells must overcome developmental negative selection, peripheral selftolerance, and tumor-induced inhibition as barriers to effective antitumor immunity. Our data suggest that neither prophylactic nor therapeutic vaccines to TAAs will be effective in preventing or treating lung cancer. Protection provided by prophylactic vaccination against an antigen relies on formation and maintenance of memory cells that can respond efficiently to tumors bearing that antigen (41) . In R26 LSL-LSIY animals, where SIY is a self-antigen, we have shown that SIY-reactive T cells do not persist and cannot result in immunologic memory or protection to SIY (data not shown; Fig. 2D ). In contrast, when targeting antigens to which the host is not tolerant, prophylactic vaccines protect against even large numbers of potentially tumorigenic cells (9) .
Therapeutic vaccines boost immune responses to tumor antigens in patients with established cancers (41) . To be effective, this requires both the presence of antigen-specific T cells and the ability to properly activate these cells. Based on our model, both elements are hampered in the context of TAAs. We have shown that central tolerance results in significant diminution of SIY TAA-specific T cells (Fig. 1C and D) . Additionally, we have shown that DC2.4.LSIY vaccination yields only marginal induction of SIY-specific cytotoxicity in mice bearing tumors overexpressing SIY (Fig. 5) . Furthermore, although WSN-SIY can endow 2C cells with high cytotoxicity, activated 2C cells are anergized and die in the presence of self-antigen (Figs. 2D and 6). Our data are consistent with observations from human trials in which therapeutic vaccines have resulted in only rare cases of objective clinical response (42) . Importantly, therapeutic vaccines may still be effective in combination with other therapeutic strategies (43) .
Immune ignorance of tumors, immune avoidance by tumors, and active suppression of antitumor immunity are the prevailing explanations for defective T-cell responses in cancer (1, 2, 36) . Loss of antigen expression or presentation is often described as a means of immune avoidance (34, 35) . We have shown sustained LSIY expression in lung cancer, even at advanced stages ( Fig. 3B and C) . Moreover, we have shown that antigen presentation was not different between R26 LSL-LSIY/+ lung tumor cell lines and controls ( Supplementary Fig. S5 ). Furthermore, we have shown the inability of 2C cells to efficiently kill nonmalignant cells expressing high SIY in SIY-overexpressing tumor-bearing hosts (Fig. 5) . These data exclude immune avoidance by tumors as a major contributor to deficient antitumor T-cell responses.
We cannot exclude the possibility of immune ignorance playing a role in early stages of tumorigenesis, but our data argue for active tumor-induced immune suppression. Inefficient 2C cell killing in mice bearing SIY-overexpressing tumors was observed even with coincident antigen presentation and costimulation provided by DC2.4.LSIY (Fig. 5 ). This treatment is normally immune-activating and, moreover, is capable of overcoming self-tolerance in tumorfree R26 LSL-LSIY/+ mice. This implies that even if tumors are naturally ignored in our model, tumor-induced T-cell suppression can dominate over immune-stimulatory signals.
There are many mechanisms by which SIY-reactive T cells may be suppressed in K-ras LSL-G12D/+ ;R26 LSL-LSIY/+ mice (2, 38) . Suppression can occur by contact with tumors or by intermediaries, but because we observe systemic antigen-specific T-cell suppression, direct contact between T cells and tumors is unlikely to be the dominant mechanism. Tumor suppression by intermediaries may involve cellular and/or soluble inhibitors of T-cell cytotoxicity. These factors may be present normally to limit self-reactivity but are increased in animals with self-antigen overexpressing tumors and thus induce greater suppression of antigen-reactive T cells. Consistent with this idea, we have shown that high levels of costimulation provided by WSN-SIY was required to effectively induce cytotoxicity in 2C cells (Fig. 5) .
We immunophenotyped animals to screen for potential cellular mediators of T-cell suppression. Two putative immunosuppressive populations, Gr1 
FoxP3
+ T regulatory cells, were reproducibly expanded in lungs and lymphoid tissues of tumor-bearing mice relative to tumor-free mice (Supplementary Fig. S6 ). Interestingly, both immune cell types are overrepresented in NSCLC patients and seem to mediate systemic immune suppression (44) (45) (46) . Further studies are needed to determine if either of these cell types are playing a causal role in tumor-induced T-cell suppression in our model.
Melanoma, ovarian, and prostate cancers are more often treated with immunotherapy in the clinic than other cancers. This may reflect an inherent susceptibility of these cancers to immune attack or simply our limited experience in using the immune system to treat other cancers. Our observations of tolerance in the presence of tumors are similar to those made in TRAMP mice in which prostate-specific expression of SV40 TAg leads to spontaneous prostate cancer (4, 5) . In contrast to our model, however, priming with a DC vaccine yielded more effective T cells that significantly reduced tumor burden in TRAMP mice (4) . Interestingly, T-cell tolerance was not observed in a mouse model of insulinoma also driven by SV40 TAg (8) . To learn more about tumor-immune interactions, it will be important to compare immune responses among different cancer types and even among tumors bearing different oncogenic alterations as particular pro-oncogenic events have been described to specifically modulate immune responses (38) . Numerous Cre-regulated oncogenes and tumor suppressor genes have been generated in the context of human cancer models (27) . Because R26 LSL-LSIY is expressed ubiquitously and independent of oncogenic events, our model tumor antigen can be studied in several cancer models to gain greater understanding of contextdependent effects on antitumor immunity. Data derived from these studies will help define the best strategies to successfully stimulate the immune system to recognize and eliminate cancers of different origins.
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